Sangamo Therapeutics, Inc. (SGMO) 股票分析

公司概述

Sangamo Therapeutics, Inc. operates as a clinical-stage genomic medicine company dedicated to translating scientific advancements into therapeutic medicines aimed at improving the lives of patients and families affected by serious diseases within the United States. The company functions within the healthcare sector, specifically in the biotechnology industry, which typically focuses on developing innovative drug candidates and therapies based on biological processes. In terms of scale, Sangamo currently maintains a market capitalization of $105.52 million while generating an annual revenue of $39.55 million over the trailing twelve-month period. The company employs 142 individuals to execute its research and development initiatives, indicating a lean organizational structure typical of early-stage biotech firms. These financial metrics, particularly the market cap and revenue figures, suggest that the company is in a development phase where valuation is driven more by pipeline potential than by established profit generation or massive revenue streams.

财务健康

The financial performance of Sangamo reveals a significant disparity between top-line revenue and bottom-line profitability, with reported revenue of $39.55 million contrasted against a net income loss of $122,932,000 for the trailing twelve months. This substantial gap between revenue and net income highlights a cost structure characterized by high operating expenses relative to sales, a common phenomenon in clinical-stage biotechnology where research and development costs are substantial before product commercialization. The company's EBITDA stands at $-104,043,000, further illustrating the heavy burn rate associated with advancing clinical-stage product candidates such as ST-920. Regarding cash flow, the entity reports a free cash flow of $-56,760,500, which indicates a consumption of cash reserves that limits immediate financial flexibility and necessitates future capital raising or funding to sustain operations. When analyzing profitability metrics, the gross margin is recorded at -184.9%, the operating margin at -175.5%, and the profit margin at 0.0%, all of which reflect the non-operational nature of the business model where costs often exceed gross revenues during the clinical trial phases. The balance sheet shows a cash position of $20.95 million against a debt level of $26.80 million, resulting in a debt-to-equity ratio listed as N/A due to the negative equity implications of the losses. This configuration suggests a leveraged balance sheet where cash on hand is insufficient to cover total debt obligations without additional financing. Liquidity is further constrained by a current ratio of 0.84, indicating that the company's current assets do not sufficiently cover its current liabilities, which poses a challenge for short-term solvency. Finally, the return metrics show a return on equity of -2891.8% and a return on assets of -83.7%, revealing that management has not yet generated positive returns on the capital invested or the assets deployed, consistent with the losses incurred by a pre-revenue or low-revenue biotechnology entity.

估值评估

Valuation metrics for Sangamo present a complex picture due to the company's unprofitable status, with a trailing twelve-month P/E ratio listed as N/A and a forward P/E of 9.55. The existence of a forward P/E figure while the trailing P/E is unavailable implies that analysts are projecting future earnings growth that could eventually make the stock profitable, though current historical earnings are negative. The price-to-book ratio is recorded at -6.21, which indicates that the market is pricing the stock significantly below its book value, a scenario often seen in companies with substantial accumulated losses or intangible assets that are not fully reflected on the balance sheet. Alternative valuation measures provide additional context, with a price-to-sales ratio of 2.67 and an EV/EBITDA of -1.07, suggesting that the market is valuing the company primarily on its revenue generation potential rather than current earnings or cash flow. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $0.84 and a 52-week low of $0.21. While the current price is not explicitly provided in the source data to calculate an exact percentage, the range demonstrates a wide trading band typical of small-cap biotechnology stocks. The beta value is 1.50, meaning the stock price is expected to be 50% more volatile than the broader market, reflecting the high risk and sensitivity to sector-specific developments inherent in clinical-stage genomic medicine companies.

Growth & Income

Revenue growth for the trailing twelve months stands at 88.4% year-over-year, while earnings growth is listed as N/A due to the company's continued net losses. The fact that earnings growth is unavailable while revenue is expanding rapidly implies that the company is scaling its operations and top line faster than it is achieving profitability, a standard trajectory for biotech firms investing heavily in clinical trials. As a non-dividend payer, Sangamo does not distribute any cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%. This absence of dividend distribution indicates that the company retains all earnings to reinvest into research and development activities rather than distributing income, a strategy necessary to fund its clinical-stage product candidates. Consequently, the overall growth and income profile is defined by rapid revenue expansion without current earnings growth or dividend income, positioning the company as a pure play on future therapeutic success rather than current cash flow generation.